Rapamycin enhanced the antitumor effects of doxorubicin in myelogenous leukemia K562 cells by downregulating the mTOR/p70S6K pathway

Chronic myelogenous leukemia (CML) is a common hematological malignancy. Some patients progressing to the blast phase develop chemotherapeutic drug resistance. In the authors' previous study, it was found that the mammalian target of rapamycin (mTOR) pathway was activated in CML and that rapamy...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jie, Liu, Wenjing, Hao, Hongling, Wang, Qiuyi, Xue, Liying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6676723/
https://www.ncbi.nlm.nih.gov/pubmed/31404320
http://dx.doi.org/10.3892/ol.2019.10589

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6676723/
https://www.ncbi.nlm.nih.gov/pubmed/31404320
http://dx.doi.org/10.3892/ol.2019.10589

Ejemplares similares